A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Considering dual biologic therapy for psoriasis or eczema? Get a firsthand account of navigating insurance, potential side effects, and treatment outcomes.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

John McEnroe is on the call of the men's championship match at Wimbledon on Sunday. The iconic American tennis player, who ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

Medically reviewed by Katlein Franca, MD Guttate psoriasis causes small, round bumps. It's typically triggered by a Streptococcus (strep) bacteria infection. Guttate psoriasis most commonly affects ...

Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...